Wealthfront Logo

ARK Genomic Revolution ETF

ARKG - Global stocks
ARKG is an actively-managed fund which invests in companies in businesses related to or benefiting from advances in genomic technology, including targeted therapeutics, bioinformatics, molecular diagnostics, and gene editing. The fund is appropriate for investors seeking long-term growth. ARKG is subject to equity market risk, and the risk that the manager’s strategy underperforms the broader equity market.
ARKG isn’t eligible for Tax-Loss Harvesting, since we can’t find a viable alternate fund.
  • Price
    $26.11
    as of 04:00 PM EST, 12/11/2024
  • Risk rating
    Very high
    We base risk ratings on the volatility, or the size and frequency of price fluctuations, of the investment. Typically, a more volatile investment has a higher risk rating.
  • Expense ratio
    0.75%
    The percentage of fund assets used to cover operating expenses and management fees.
  • 52-week high
    $34.37
    The highest share price in the past year.
  • 52-week low
    $22.27
    The lowest share price in the past year.
  • Dividend yield
    The average percentage of dividends paid relative to the share price over the past year.
  • Net assets
    $1.23B
    The total value of all assets held by the fund.
  • Volume
    2,306,148
    The average trading volume over the past 90 days.
View prospectus

Investing is easy

when it’s automated

Start with one of Wealthfront’s expert-built portfolios and then customize your portfolio with hundreds of investment possibilities.

Get started